

Concise synthesis of a heptasaccharide antigen found in the cell-wall lipopolysaccharide of *Mycobacterium gordonae* strain 990

Rajib Panchadhayee · Anup Kumar Misra

Received: 12 January 2008 / Revised: 28 March 2008 / Accepted: 5 May 2008 / Published online: 21 June 2008
© Springer Science + Business Media, LLC 2008

Abstract A straight forward synthesis of a heptasaccharide part of the cell-wall lipopolysaccharide of *Mycobacterium gordonae* strain 990, known to have antigenicity, has been achieved in excellent yield. Judicious choice of protecting groups in the intermediates played a significant role throughout the synthesis. Most of the intermediate steps furnished satisfactory yield.

Keywords Oligosaccharides · Glycosylations · Antigens · Vaccines · *Mycobacterium gordonae* 990

Introduction

Since the emergence of acquired immunodeficiency syndrome (AIDS), mycobacterial infection has become a serious concern [1, 2]. In AIDS patients, infections due to non-tubercular mycobacteria (NTM) other than tuberculosis are gradually increasing causing severe problems associated with unnecessary treatments with therapeutics [3, 4]. Among several NTM species isolated from soil and water [5], *Mycobacterium gordonae* (*M. gordonae*) is one of the important organisms, which requires extra attention. Other than soil and water *M. gordonae* can be found in the sputum, urine and gastric juice in human [6]. Earlier it was considered as a friendly organism and often called as “*Mycobacterium aque* or tap-water bacillus” [7]. After-

wards, a number of infections in the skin, soft tissues, respiratory tract, liver and immunosuppression associated with this species have been reported [8, 9]. In HIV infected patients this particular species causes serious pulmonary infections, which are indistinguishable from the tuberculosis. As a result, treatment with currently available anti-tubercular drugs e.g. isoniazid, pyrazinamide, ethambutol and cycloserine can not cure the patient as *M. gordonae* is resistant to these drugs [8, 9]. Therefore, urgent attention is essential to identify such atypical *Mycobacteria* from other species of *Mycobacteria* for the proper drug administration and thereby AIDS management.

M. gordonae 990 strain is a member of atypical NTM, which causes several pulmonary infections in AIDS patients. The cell-wall of this particular strain contains a large number of glycolipids and some of them are antigenic in nature. Brennan *et al.* have isolated and determined the structure of a unique trehalose linked heptasaccharide moiety having antigenic activity (Fig. 1) [10]. As an antigenic oligosaccharide can produce specific immune response in the host by developing specific antibodies, this particular heptasaccharide moiety could also provide useful serodiagnosis of the mycobacterial infection by developing specific antibodies and thus help to design an antibacterial vaccine candidate against this strain.

Although, glycoconjugate vaccines are highly effective to control several bacterial infections, numbers of chemically synthesized carbohydrate vaccines are limited. In most of the glycoconjugate vaccines, the oligosaccharide parts were isolated from natural sources. However, a number of reports appeared in the literature for the development of the synthetic glycoconjugate vaccines against several bacterial infections [11–21]. As cell-wall oligosaccharides having antigenicity are attractive targets for the development of glycoconjugate vaccine candidates, their limited availability

C.D.R.I. communication number 7377.

R. Panchadhayee · A. Kumar Misra (✉)
Medicinal and Process Chemistry Division,
Central Drug Research Institute,
Chattar Manzil Palace,
Lucknow 226 001, India
e-mail: akmisra69@rediffmail.com




Fig. 1 Structure of the heptasaccharide antigen found in the cell-wall of *M. gordonae* 990

from the natural source set the challenges to the organic chemists to develop concise synthetic protocols for their large scale preparation. In order to develop a specific immune response in the host with the synthetic glycoconjugate vaccine candidate, it is essential to link the synthetic oligosaccharide moiety with a protein through a spacer linkage. Therefore, it is recommended that the reducing end of the synthetic oligosaccharide moiety should contain a temporary protecting group, which can be removed during the process of conjugation with the protein. Although, synthesis of a tetrasaccharide methyl glycoside related to the heptasaccharide moiety was reported earlier [22], total synthesis of the full heptasaccharide with temporary anomeric protecting group was not attempted. In this communication, we present a concise chemical synthesis of the full heptasaccharide antigen found in the cell-wall lipopolysaccharide of *M. gordonae* strain 990 as its 4-methoxyphenyl glycoside (Fig. 2).

Results and discussion

The synthesis of the target heptasaccharide **1** was achieved by judicious functional group manipulations and stereoselective glycosylations. Several differentially protected monosaccharide derivatives (Fig. 3), prepared from commercially available sugars using reported methodologies [23] have been used to construct the target molecule **1**.

Ethyl 4-*O*-benzyl-2-*O*-(4-methoxybenzyl)-3-*O*-methyl-1-thio- α -L-rhamnopyranoside (**6**) was prepared from ethyl 4-*O*-benzyl-1-thio- α -L-rhamnopyranoside (**8**) [24] in excellent yield following a tin mediated selective methylation followed by 4-methoxybenzylolation under alkaline conditions (Scheme 1).




Fig. 2 Chemical structure of the synthesized heptasaccharide as its 4-methoxyphenyl glycoside (**1**)






Fig. 3 Suitably protected monosaccharide building blocks used for the construction of heptasaccharide (**1**) as its 4-methoxyphenyl glycoside

Sequential stereoselective glycosylations and protecting group manipulations for the synthesis of target heptasaccharide **1** is presented in Scheme 1 and 2. Compounds **2** and **3** were coupled together stereoselectively to furnish disaccharide derivative **9**, which was transformed into the disaccharide acceptor **10** following an earlier reported reaction conditions [23]. *N*-Iodosuccinimide (NIS)-trimethylsilyl trifluoromethanesulfonate (TMSOTf) [25, 26] mediated β -selective glycosylation of disaccharide derivative **10** with thioglycoside **3** afforded trisaccharide derivative **11** in 80% yield, which was benzylated to furnish trisaccharide derivative **12** under a one-pot deacetylation-benzylation protocol reported earlier [27]. Exclusive formation of β -glycosidic linkage in the compound **11** was achieved, due to the presence of an *O*-acetyl group at the C-2 position of the thioglycoside donor **3**, which was confirmed by the signature peaks that appeared in its NMR spectra e. g. δ [5.49 (s, PhCH), 5.27 (br s, H-1_A), 5.17 (s, PhCH), 4.88 (d, J =8.0 Hz, H-1_B), 4.91 (d, J =8.0 Hz, H-1_C) in ¹H NMR and δ [103.6 (C-1_C), 101.6 (PhCH), 100.8 (PhCH), 100.6 (C-1_B), 97.3 (C-1_A)] in ¹³C NMR spectra. Oxidative removal of 4-methoxybenzyl group in compound **12** using DDQ [28] afforded the trisaccharide acceptor **13**, which was coupled with 2-*O*-acetylated thioglycoside donor **5** to furnish tetrasaccharide derivative **14** in 77% yield exploiting neighboring group participation. Signals in the NMR spectra of compound **14** confirmed the α -selective 1,2-*trans* glycosylation [δ 5.30 (br s, 1 H, H-1_A), 4.97 (br s, 1 H, H-1_D) in ¹H NMR and δ 103.4 (C-1_C), 102.1 (C-1_B), 101.5 (PhCH), 101.2 (PhCH), 97.8 (C-1_D), 97.3 (C-1_A) in ¹³C NMR spectra]. Saponification of compound **14** gave tetrasaccharide acceptor **15**, which on NIS-TMSOTf mediated glycosylation with the D-xylose




Scheme 1 Reagents: *a* (1) Bu₂SnO, toluene, 110°C, 4 h, then iodomethane, TBAB, r t, 48 h; (2) 4-methoxybenzyl chloride, NaOH, DMF, r t, 3 h, 75% in two steps



Scheme 2 Reagents: *a* *N*-Iodosuccinimide, TMSOTf, CH₂Cl₂, MS-4 Å, -40°C, 80% for 11, 77% for 14, 78% for 16; *b* benzyl bromide, NaOH, TBAB, DMF, r t, 3 h, 85%; *c* DDQ, CH₂Cl₂-H₂O, r t, 2 h, 77% for 13 and 80% for 17; *d* CH₃ONa, CH₃OH, r t, 2 h, quantitative

derived thioglycoside donor **7** furnished pentasaccharide derivative **16** in 78% yield. As mentioned earlier stereo-selective 1,2-*trans* glycosylation was achieved, due to the presence of an *O*-acetyl group at the C-2 position of

compound **7**, which was confirmed from the 1D and 2D NMR spectra of compound **16** [δ 4.10 (d, $J=7.2$ Hz, H-1_E, β -D-Xylp) in ¹H NMR and 103.4 (C-1_C), 102.5 (C-1_B), 101.9 (C-1_E), 101.5 (PhCH), 101.3 (PhCH), 99.2 (C-1_D), 97.2 (C-1_A) in ¹³C NMR]. Compound **16** was allowed to react with DDQ to furnish pentasaccharide acceptor **17** via oxidative removal of 4-methoxybenzyl group (Scheme 2). Compound **17** was allowed to couple with thioglycoside donor **6** under NIS-TMSOTf mediated glycosylation conditions to afford hexasaccharide **18**. Although in this case, due to the presence of the 4-methoxybenzyl group, a non-participating functional group at the C-2 position of L-rhamnosyl donor, there was a chance of formation of some β -L-rhamnose linked hexasaccharide derivative together with required compound **18**, spectral data of compound **18** confirmed the formation of only the α -linked required product [signals at δ 5.51 (s, PhCH), 5.30 (d, $J=1.7$ Hz, H-1_A), 5.28 (s, PhCH), 5.08 (br s, H-1_D), 5.05 (br s, H-1_F), 4.97 (d, $J=7.8$ Hz, H-1_B), 4.90 (d, $J=8.1$ Hz, H-1_C), 4.70 (d, $J=7.2$ Hz, H-1_E) in ¹H NMR, signals at δ 103.3 (C-1_C), 102.0 (C-1_B), 101.2 (2 C, 2 PhCH), 100.7 (C-1_E), 99.4 (C-1_F), 98.7 (C-1_D), 97.1 (C-1_A) in ¹³C NMR and proton coupled ¹³C NMR spectra [$J_{C-1/H-1}$ 160 Hz, 160 Hz (2 β -D-Glcp), 164 Hz (β -D-Xylp), 172 Hz, 172 Hz and 170 Hz (3 α -L-Rhap)]. The values of the coupling constants ($J_{C-1/H-1}$) being above 165 Hz for L-rhamnose moieties confirmed their α -linkages [22, 29]. Compound **18** was treated with DDQ under similar reaction conditions mentioned earlier to generate hexasaccharide acceptor **19** in 80% yield. Finally, iodonium ion catalyzed α -selective glycosylation of compound **19** with per-*O*-acetylated thioglycoside donor **4** furnished heptasaccharide derivative **20** in 85% yield, which on global deprotection of functional groups involving saponification and hydrogenolysis [30] resulted the target heptasaccharide **1** as its 4-methoxyphenyl glycoside. Formation of the required glycosyl linkage in compound **20** was confirmed from its spectral data [signals at δ 102.2 (C-1_C), 101.1 (C-1_B), 100.2 (2 C, PhCH), 99.6 (C-1_F), 99.4 (C-1_E), 97.7 (2 C, C-1_D and C-1_G), 96.1 (C-1_A) in ¹³C NMR spectrum]. Compound **1** was characterized by its 1D and 2D spectral analysis [signals at δ 5.39 (br s, 1 H, H-1_G), 5.33 (br s, 1 H, H-1_A), 5.26 (br s, 1 H, H-1_D), 4.92 (br s, 1 H, H-1_F), 4.70 (d, $J=7.5$ Hz, 1 H, H-1_B), 4.63 (d, $J=7.5$ Hz, 1 H, H-1_C), 4.54 (d, $J=7.2$ Hz, 1 H, H-1_E) in the ¹H NMR and at δ 105.0 (C-1_E), 103.9 (C-1_B), 103.5 (C-1_C), 101.7 (C-1_F), 100.7 (C-1_D), 100.0 (C-1_G), 99.0 (C-1_A) in the ¹³C NMR spectra] (Scheme 3). Use of functional groups with participating ability (*O*-acetyl) at C-2 positions of the glycosyl donors resulted in the required stereo-outcome in all 1,2-*trans* glycosylation products. General glycosylation conditions and a similar kind of protecting group strategy were adopted to make this synthetic strategy useful for a scale-up preparation.



Scheme 3 Reagents: *a* *N*-Iodosuccinimide, TMSOTf, CH₂Cl₂, MS-4 Å, -30°C, 30 min, 74% for 18, 85% for 20; *b* DDQ, CH₂Cl₂-H₂O, r t, 2 h, 80%; *c* CH₃ONa, CH₃OH, r t, 2 h; *d* H₂, 20% Pd(OH)₂-C, CH₃OH, r t, 24 h, 76% in two steps

Conclusion

In summary, a concise chemical synthesis of the heptasaccharide motif as its 4-methoxyphenyl glycoside found in the cell-wall of *Mycobacterium gordonae* strain 990 has been achieved using general glycosylation conditions and a similar type of protecting group manipulations. This synthetic sequence can also be applied to a scale-up preparation on demand. All glycosylation steps are reasonably fast, stereoselective, high yielding and highly reproducible. Most of the intermediates were solid and characterized with the help of NMR and mass spectral analysis. 4-Methoxy phenyl group can serve as a temporary anomeric protecting group, which can be oxidatively removed using ammonium ceric nitrate (CAN) to couple the heptasaccharide moiety to a carrier protein for the preparation of glycoconjugate antigens.

Experimental section

General methods All the reactions were monitored by thin layer chromatography over silica gel coated TLC plates. The spots on TLC were visualized by warming ceric sulphate (2% Ce(SO₄)₂ in 2N H₂SO₄) sprayed plates on a hot plate. Silica gel 230–400 mesh was used for column chromatography. ¹H and ¹³C NMR (¹H coupled and

decoupled), 2D COSY, and HSQC spectra were recorded on Bruker Advance DPX 300 MHz using CDCl₃ and D₂O as solvents and TMS as internal reference unless stated otherwise. Chemical shift values are expressed in δ ppm. ESI-MS were recorded on a MICROMASS QUTTRO II triple quadrupole mass spectrometer. Elementary analysis was carried out on Carlo ERBA-1108 analyzer. Optical rotations were measured at 25°C on a Rudolf Autopol III polarimeter. Commercially available grades of organic solvents of adequate purity are used in many reactions.

Ethyl 4-*O*-benzyl-2-*O*-(4-methoxybenzyl)-3-*O*-methyl-1-thio- α -*L*-rhamnopyranoside (6) To a solution of compound **8** (7.5 g, 25.1 mmol) in toluene (200 mL) was added dibutyltin oxide (7.5 g, 30.1 mmol) and the reaction mixture was allowed to stir at 110°C with azeotropic removal of water for 4 h. The solvents were reduced to half of the volume and iodomethane (6.3 mL, 101.2 mmol) and tetrabutylammonium bromide (1 g) were added to it and the reaction mixture was stirred at room temperature for 48 h. The solvents were removed under reduced pressure and crude product was diluted with CH₂Cl₂ (150 mL). The organic layer was washed with 1 N aq. HCl, satd. NaHCO₃ and water in succession, dried (Na₂SO₄) and concentrated under reduced pressure. To a solution of the crude product in DMF (50 mL) were added powdered NaOH (3 g, 75 mmol), 4-methoxybenzyl chloride (6 mL, 44.2 mmol) and the reaction mixture was allowed to stir at room temperature for 3 h. The reaction mixture was diluted with water (150 mL) and extracted with CH₂Cl₂ (150 mL). The organic layer was washed with water, dried (Na₂SO₄) and evaporated to dryness. The crude product was purified over SiO₂ using hexane-EtOAc (5:1) as eluant to furnish pure compound **6** (8.2 g, 75%); colorless oil; [α]_D²⁵ -47.1 (*c* 1.5, CHCl₃); IR (neat): 2925, 2361, 1612, 1512, 1457, 1219, 1099, 1032, 758 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.35–7.26 (m, 7 H, Ar-H), 6.90 (d, *J*=8.6 Hz, 2 H, Ar-H), 5.24 (br s, 1 H, H-1), 4.94 (d, *J*=11.2 Hz, 1 H, PhCH₂), 4.71–4.60 (m, 3 H, PhCH₂), 3.99 (t, *J*=7.0 Hz, 1 H, H-4), 3.86–3.85 (m, 1 H, H-5), 3.83 (s, 3 H, OCH₃), 3.56–3.47 (m, 2 H, H-2 and H-3), 3.38 (s, 3 H, OCH₃), 2.66–2.52 (m, 2 H, SCH₂CH₃), 1.33 (d, *J*=6.2 Hz, 3 H, CCH₃), 1.27 (t, *J*=7.4 Hz, 3 H, SCH₂CH₃); ¹³C NMR (75 MHz, CDCl₃): δ 159.3–113.8 (Ar-C), 82.3 (C-1), 81.9 (C-4), 80.6 (C-2), 75.4, 75.1 (2 PhCH₂), 71.8 (C-3), 68.2 (C-5), 57.4 (OCH₃), 55.1 (OCH₃), 25.4 (SCH₂CH₃), 17.9 (CCH₃), 15.1 (SCH₂CH₃); ESI-MS: *m/z*=455.2 [M+Na]⁺; Anal. Calcd. for C₂₄H₃₂O₅S (432.20): C, 66.64; H, 7.46; found: C, 66.43; H, 7.70.

4-Methoxyphenyl [2-*O*-acetyl-4,6-*O*-benzylidene-3-*O*-(4-methoxybenzyl)- β -*D*-glucopyranosyl]-(1 \rightarrow 3)-(2-*O*-benzyl-4,6-*O*-benzylidene- β -*D*-glucopyranosyl)-(1 \rightarrow 3)-2,

4-di-O-benzyl- α -L-rhamnopyranoside (11) To a solution of compound **10** (4 g, 5 mmol) and compound **3** (2.9 g, 6.1 mmol) in dry CH_2Cl_2 (30 mL) was added MS 4 Å (3 g) and the reaction mixture was allowed to stir at room temperature for 30 min under argon. After cooling the reaction mixture to -40°C , *N*-iodosuccinimide (1.7 g, 7.5 mmol) and TMSOTf (50 μL , 0.27 mmol) were added to it. The reaction mixture was stirred at -40°C for 30 min and quenched with Et_3N (0.2 mL). The reaction mixture was filtered and washed with CH_2Cl_2 (30 mL). The organic layer was washed successively with aq. $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (Na_2SO_4) and concentrated under reduced pressure to give the crude product, which was purified over SiO_2 using hexane-EtOAc (6:1) as eluant to furnish pure **11** (4.8 g, 80%); colorless solid; m.p. $86\text{--}87^\circ\text{C}$; $[\alpha]_{\text{D}}^{25} -42.7$ (*c* 1.5, CHCl_3); IR (KBr): 2924, 1749, 1608, 1504, 1407, 1232, 1091, 1030, 754 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.48–7.07 (m, 27 H, Ar-H), 6.88 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.79–6.74 (m, 4 H, Ar-H), 5.49 (s, 1 H, PhCH), 5.27 (br s, 1 H, H-1_A), 5.17 (s, 1 H, PhCH), 4.99 (t, $J=8.0$ Hz, 1 H, H-2_C), 4.93 (d, $J=11.6$ Hz, 1 H, PhCH₂), 4.91 (d, $J=8.0$ Hz, 1 H, H-1_C), 4.88 (d, $J=8.0$ Hz, 1 H, H-1_B), 4.85 (d, $J=12.1$ Hz, 1 H, PhCH₂), 4.75 (d, $J=12.1$ Hz, 1 H, PhCH₂), 4.73–4.68 (m, 3 H, PhCH₂), 4.59 (d, $J=11.8$ Hz, 1 H, PhCH₂), 4.36–4.28 (m, 3 H, H-3_A, H-6_{aC} and PhCH₂), 4.14–4.09 (m, 1 H, H-6_{aB}), 3.96–3.95 (m, 1 H, H-2_A), 3.90–3.77 (m, 3 H, H-3_B, H-3_C and H-6_{bC}), 3.76, 3.74 (2 s, 6 H, 2 OCH₃), 3.71–3.51 (m, 5 H, H-4_A, H-4_B, H-5_B, H-5_C and H-6_{bB}), 3.43 (t, $J=8.1$ Hz, 1 H, H-2_B), 3.36–3.28 (m, 2 H, H-4_C and H-5_A), 1.78 (s, 3 H, COCH₃), 1.27 (d, $J=6.3$ Hz, 3 H, CCH₃); ^{13}C NMR (75 MHz, CDCl_3): δ 169.0 (COCH₃), 159.2–113.6 (Ar-C), 103.6 (C-1_C), 101.6 (PhCH), 100.8 (PhCH), 100.6 (C-1_B), 97.3 (C-1_A), 82.7 (C-2_B), 81.5 (C-5_C), 80.7 (C-5_B), 79.7 (C-3_C), 78.9 (C-4_B), 78.4 (C-3_B), 78.1 (C-2_A), 77.0 (C-2_C), 75.4 (PhCH₂), 74.5 (PhCH₂), 73.7 (PhCH₂), 73.4 (C-3_A), 72.9 (PhCH₂), 68.7 (C-6_B), 68.6 (C-6_C), 68.5 (C-4_A), 66.3 (C-5_A), 65.9 (C-4_C), 55.5 (OCH₃), 55.1 (OCH₃), 20.7 (COCH₃), 18.0 (CCH₃); ESI-MS: $m/z=1225.6$ $[\text{M}+\text{Na}]^+$; Anal. Calcd. for $\text{C}_{70}\text{H}_{74}\text{O}_{18}$ (1202.48): C, 69.87; H, 6.20; found: C, 69.70; H, 6.46.

4-Methoxyphenyl [2-O-benzyl-4,6-O-benzylidene-3-O-(4-methoxybenzyl)- β -D-glucopyranosyl]-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4-di-O-benzyl- α -L-rhamnopyranoside (12) To a solution of compound **11** (4.5 g, 3.74 mmol) in DMF (50 mL) were added benzyl bromide (0.9 mL, 7.6 mmol), TBAB (0.2 g), powdered NaOH (450 mg, 11.2 mmol) and the reaction mixture was allowed to stir at room temperature for 3 h. The reaction mixture was diluted with water (150 mL) and extracted with CH_2Cl_2 (100 mL). The organic layer was washed with water, dried (Na_2SO_4) and concentrated to give the crude product, which was purified over SiO_2 using

hexane-EtOAc (4:1) as eluant to furnish pure **12** (4 g, 85%); colorless solid; m.p. $67\text{--}69^\circ\text{C}$; $[\alpha]_{\text{D}}^{25} -31.3$ (*c* 1.5, CHCl_3); IR (KBr): 2926, 1720, 1613, 1508, 1456, 1367, 1247, 1219, 1080, 827, 739, 699 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.51–7.17 (m, 32 H, Ar-H), 6.95 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.80–6.77 (m, 4 H, Ar-H), 5.55 (s, 1 H, PhCH), 5.33 (d, $J=1.7$ Hz, 1 H, H-1_A), 5.31 (s, 1 H, PhCH), 5.07–4.95 (m, 2 H, PhCH₂), 4.93 (d, $J=8.0$ Hz, 1 H, H-1_C), 4.84 (d, $J=7.7$ Hz, 1 H, H-1_B), 4.82–4.63 (m, 7 H, PhCH₂), 4.39–4.34 (m, 3 H, H-3_A, H-6_{aC} and PhCH₂), 4.27–4.20 (m, 1 H, H-6_{aB}), 4.02 (t, $J=8.5$ Hz, 1 H, H-3_C), 3.99–3.97 (m, 1 H, H-2_A), 3.86–3.78 (m, 2 H, H-3_B and H-4_A), 3.79 (s, 6 H, 2 OCH₃), 3.76–3.72 (m, 1 H, H-6_{bC}), 3.70–3.63 (m, 4 H, H-4_B, H-4_C, H-5_B and H-6_{bB}), 3.54 (t, $J=8.0$ Hz, H-2_C), 3.51 (t, $J=7.6$ Hz, 1 H, H-2_B), 3.48–3.40 (m, 1 H, H-5_A), 3.38–3.30 (m, 1 H, H-5_C), 1.28 (d, $J=6.0$ Hz, 3 H, CCH₃); ^{13}C NMR (75 MHz, CDCl_3): δ 159.4–113.6 (Ar-C), 103.5 (C-1_C), 102.2 (PhCH), 101.5 (PhCH), 100.8 (C-1_B), 97.4 (C-1_A), 83.3 (C-2_B), 82.2 (C-5_C), 81.5 (C-5_B), 81.2 (C-3_A), 80.2 (C-3_C), 79.7 (C-4_B), 78.5 (C-3_B), 78.2 (C-2_A), 77.0 (C-2_C), 75.1 (PhCH₂), 74.5 (2 C, PhCH₂), 74.0 (PhCH₂), 73.7 (PhCH₂), 68.9 (2 C, C-6_B and C-6_C), 68.6 (C-4_A), 66.2 (C-5_A), 65.7 (C-4_C), 55.5 (OCH₃), 55.0 (OCH₃), 17.9 (CCH₃); ESI-MS: $m/z=1268.5$ $[\text{M}+\text{NH}_4]^+$; Anal. Calcd. for $\text{C}_{75}\text{H}_{78}\text{O}_{17}$ (1250.52): C, 71.98; H, 6.28; found: C, 71.78; H, 6.54.

4-Methoxyphenyl (2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4-di-O-benzyl- α -L-rhamnopyranoside (13) To a solution of compound **12** (3.8 g, 3 mmol) in CH_2Cl_2 and water (50 mL, 1:1), was added DDQ (820 mg, 3.6 mmol) and the reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture was diluted with CH_2Cl_2 (50 mL) and the organic layer was washed successively with satd. aq. NaHCO_3 and water, dried (Na_2SO_4) and concentrated under reduced pressure to give the crude product, which was purified over SiO_2 using hexane-EtOAc (4:1) to furnish pure **13** (2.6 g, 77%); colorless solid; m.p. $96\text{--}98^\circ\text{C}$; $[\alpha]_{\text{D}}^{25} -40.3$ (*c* 1.5, CHCl_3); IR (KBr): 2874, 1632, 1506, 1457, 1378, 1220, 1091, 1033, 998, 745, 698 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.50–7.07 (m, 30 H, Ar-H), 6.92 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.78 (d, $J=9.0$ Hz, 2 H, Ar-H), 5.52 (s, 1 H, PhCH), 5.32 (s, 1 H, PhCH), 5.30 (d, $J=1.6$ Hz, 1 H, H-1_A), 5.01 (d, $J=8.0$ Hz, 1 H, H-1_C), 4.99 (d, $J=7.9$ Hz, 1 H, H-1_B), 4.96 (d, $J=11.7$ Hz, 1 H, PhCH₂), 4.89 (d, $J=11.7$ Hz, 1 H, PhCH₂), 4.85 (d, $J=12.0$ Hz, 1 H, PhCH₂), 4.78 (d, $J=11.7$ Hz, 1 H, PhCH₂), 4.71–4.65 (m, 3 H, PhCH₂), 4.37–4.32 (m, 3 H, H-3_A, H-6_{aC} and PhCH₂), 4.24–4.19 (m, 1 H, H-6_{aB}), 4.01 (t, $J=8.9$ Hz, 1 H, H-3_C), 3.97–3.95 (m, 1 H, H-2_A), 3.85–3.76 (m, 1 H, H-4_A), 3.75 (s, 3 H, OCH₃), 3.73–3.69 (m, 1 H, H-3_B), 3.67–3.57 (m, 3 H, H-4_C, H-6_{bB}

and H-6_{BC}), 3.55–3.48 (m, 3 H, H-2_C, H-4_B and H-5_B), 3.47–3.28 (m, 3 H, H-2_B, H-5_A and H-5_C), 1.27 (d, $J=6.0$ Hz, 3 H, CCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 150.2–114.5 (Ar-C), 103.5 (C-1_C), 102.4 (C-1_B), 101.5 (PhCH), 101.4 (PhCH), 97.2 (C-1_A), 83.1 (C-5_B), 82.2 (C-2_B), 81.5 (C-5_C), 80.5 (C-4_B), 79.5 (C-3_A), 78.5 (C-2_A), 78.4 (C-3_C), 76.8 (C-2_C), 75.1 (PhCH₂), 74.4 (2 C, 2 PhCH₂), 73.6 (PhCH₂), 73.3 (C-3_B), 68.7 (2 C, C-6_B and C-6_C), 68.5 (C-4_A), 66.2 (C-5_A), 65.7 (C-4_C), 55.4 (OCH₃), 17.9 (CCH₃); ESI-MS: $m/z=1153.5$ [M+Na]⁺; Anal. Calcd. for C₆₇H₇₀O₁₆ (1130.46): C, 71.13; H, 6.24; found: C, 70.92; H, 6.50.

4-Methoxyphenyl [2-O-acetyl-4-O-benzyl-3-O-(4-methoxybenzyl)-α-L-rhamnopyranosyl]-(1→3)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→3)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→3)-2,4-di-O-benzyl-α-L-rhamnopyranoside (14) To a solution of compound **13** (2.5 g, 2.2 mmol) and compound **5** (1.2 g, 2.6 mmol) in dry CH₂Cl₂ (25 mL) was added MS 4 Å (2 g) and the reaction mixture was stirred at room temperature for 30 min under argon. The reaction mixture was cooled to –40°C and *N*-iodosuccinimide (700 mg, 3.1 mmol) and TMSOTf (20 μL, 0.12 mmol) were added to it. The mixture was stirred at –40°C for 30 min and quenched with Et₃N (0.1 mL). The reaction mixture was filtered and washed with CH₂Cl₂ (50 mL). The filtrate was successively washed with 10% aq Na₂S₂O₃ and water, dried (Na₂SO₄) and concentrated under reduced pressure to give crude product, which was purified over SiO₂ using hexane-EtOAc (4:1) as eluant to furnish pure **14** (2.6 g, 77%); colorless solid; m.p. 100–101°C; [α]_D²⁵ –38.6 (*c* 1.5, CHCl₃); IR (KBr): 2926, 2361, 1741, 1705, 1510, 1459, 1374, 1238, 1090, 754, 697 cm^{–1}; ¹H NMR (300 MHz, CDCl₃): δ 7.46–7.09 (m, 37 H, Ar-H), 6.89 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.78–6.74 (m, 4 H, Ar-H), 5.49 (s, 1 H, PhCH), 5.38–5.36 (m, 1 H, H-2_D), 5.30 (br s, 1 H, H-1_A), 5.25 (s, 1 H, PhCH), 5.02–4.98 (m, 3 H, H-1_B, H-1_C and PhCH₂), 4.97 (br s, 1 H, H-1_D), 4.94–4.77 (m, 5 H, PhCH₂), 4.70–4.58 (m, 4 H, PhCH₂), 4.51 (d, $J=11.2$ Hz, 1 H, PhCH₂), 4.38–4.31 (m, 4 H, H-3_A, H-4_D, H-6_{AC} and PhCH₂), 4.24–4.17 (m, 1 H, H-6_{AB}), 4.08–4.0 (m, 2 H, H-3_C and H-4_C), 3.97–3.95 (m, 1 H, H-2_A), 3.85–3.79 (m, 3 H, H-3_B, H-3_D and H-6_{BC}), 3.74, 3.72 (2 s, 6 H, 2 OCH₃), 3.70–3.59 (m, 4 H, H-4_A, H-5_B, H-5_D and H-6_{BB}), 3.58–3.40 (m, 3 H, H-2_B, H-2_C and H-4_B), 3.35–3.20 (m, 2 H, H-5_A and H-5_C), 2.03 (s, 3 H, COCH₃), 1.27 (d, $J=6.0$ Hz, 3 H, CCH₃), 0.93 (d, $J=6.0$ Hz, 3 H, CCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 169.7 (COCH₃), 159.2–113.7 (Ar-C), 103.4 (C-1_C), 102.1 (C-1_B), 101.5 (PhCH), 101.2 (PhCH), 97.8 (C-1_D), 97.3 (C-1_A), 83.3 (C-2_B), 82.6 (C-2_C), 81.5 (C-5_B), 80.1 (C-3_C), 79.6 (C-5_C), 79.0 (C-5_D), 78.5 (C-2_A), 77.8 (2 C, C-3_B and C-3_D), 76.9 (C-3_A), 76.3 (C-4_B), 75.1 (PhCH₂), 74.9

(PhCH₂), 74.6 (PhCH₂), 74.5 (PhCH₂), 73.7 (PhCH₂), 71.4 (PhCH₂), 68.9 (2 C, C-6_B and C-6_C), 68.7 (C-2_D), 68.6 (C-4_A), 67.5 (C-4_C), 66.2 (C-5_A), 66.0 (C-4_D), 55.4 (OCH₃), 55.0 (OCH₃), 20.9 (COCH₃), 17.9 (CCH₃), 17.5 (CCH₃); ESI-MS: $m/z=1546.7$ [M+NH₄]⁺; Anal. Calcd. for C₉₀H₉₆O₂₂ (1528.64): C, 70.66; H, 6.33; found: C, 70.48; H, 6.55.

4-Methoxyphenyl [4-O-benzyl-3-O-(4-methoxybenzyl)-α-L-rhamnopyranosyl]-(1→3)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→3)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→3)-2,4-di-O-benzyl-α-L-rhamnopyranoside (15) A solution of the compound **14** (2.5 g, 1.6 mmol) in 0.1 M CH₃ONa in CH₃OH (50 mL) was allowed to stir at room temperature for 2 h, neutralized with Amberlite IR-120 (H⁺) resin, filtered and concentrated. The crude product was passed through a short pad of SiO₂ using hexane-EtOAc (3:1) to give pure compound **15** (2.4 g, quantitative); colorless solid; m.p. 92–94°C; [α]_D²⁵ –55.6 (*c* 1.5, CHCl₃); IR (KBr): 2927, 1620, 1508, 1457, 1377, 1220, 1093, 1036, 744, 697 cm^{–1}; ¹H NMR (300 MHz, CDCl₃): δ 7.47–7.01 (m, 37 H, Ar-H), 6.93 (d, $J=9.0$ Hz, Ar-H), 6.81–6.76 (m, 4 H, Ar-H), 5.50 (s, 1 H, PhCH), 5.31 (d, $J=1.7$ Hz, 1 H, H-1_A), 5.28 (s, 1 H, PhCH), 5.06 (br s, 1 H, H-1_D), 4.98 (2 d, $J=7.7$ Hz, 2 H, H-1_B and H-1_C), 4.95–4.75 (m, 5 H, PhCH₂), 4.70 (d, $J=12.0$ Hz, 1 H, PhCH₂), 4.63–4.47 (m, 5 H, PhCH₂), 4.37–4.31 (m, 3 H, H-3_A, H-6_{AC} and PhCH₂), 4.24–4.19 (m, 1 H, H-6_{AB}), 4.03–3.94 (m, 3 H, H-2_A, H-3_C and H-3_D), 3.82–3.76 (m, 2 H, H-3_B and H-4_D), 3.75, 3.73 (2 s, 6 H, 2 OCH₃), 3.72–3.70 (m, 1 H, H-6_{BC}), 3.69–3.60 (m, 3 H, H-2_D, H-4_A and H-6_{BB}), 3.58–3.32 (m, 6 H, H-2_B, H-4_B, H-4_C, H-5_A, H-5_B and H-5_D), 3.30–3.22 (m, 2 H, H-2_C and H-5_C), 1.27 (d, $J=6.0$ Hz, 3 H, CCH₃), 0.87 (d, $J=6.0$ Hz, 3 H, CCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 159.2–113.8 (Ar-C), 103.4 (C-1_C), 102.5 (C-1_B), 101.3 (2 C, 2 PhCH), 99.5 (C-1_D), 97.1 (C-1_A), 83.2 (C-2_B), 82.5 (C-2_C), 81.5 (C-5_B), 80.1 (C-3_C), 79.5 (C-5_C), 79.4 (C-4_A), 79.2 (C-2_A), 78.4 (C-3_D), 78.2 (C-3_B), 76.8 (2 C, C-3_A and C-4_B), 75.2, 74.9, 74.6, 74.5, 73.6 (5 PhCH₂), 68.8 (2 C, C-6_B and C-6_C), 68.5 (C-2_D), 68.4 (C-5_D), 67.2 (C-4_C), 66.2 (C-5_A), 66.0 (C-4_D), 55.4 (OCH₃), 55.0 (OCH₃), 17.9, 17.3 (2 CCH₃); ESI-MS: $m/z=1504.6$ [M+NH₄]⁺; Anal. Calcd. for C₈₈H₉₄O₂₁ (1486.63): C, 71.05; H, 6.37; found: C, 70.84; H, 6.62.

4-Methoxyphenyl (2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-(1→2)-[4-O-benzyl-3-O-(4-methoxybenzyl)-α-L-rhamnopyranosyl]-(1→3)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→3)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1→3)-2,4-di-O-benzyl-α-L-rhamnopyranoside (16) To a solution of compound **15** (2.3 g, 1.5 mmol) and compound **7** (0.6 g, 1.9 mmol) in dry CH₂Cl₂ (20 mL) was added MS 4 Å (1 g) and the reaction

mixture was stirred at room temperature for 30 min under argon. The reaction mixture was cooled to -40°C and *N*-iodosuccinimide (500 mg, 2.2 mmol) and TMSOTf (15 μL , 0.08 mmol) were added to it. The mixture was stirred at the same temperature for 30 min and quenched with Et_3N (0.1 mL). The reaction mixture was filtered and washed with CH_2Cl_2 (50 mL). The organic layer was washed successively with 10% aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried (Na_2SO_4) and concentrated under reduced pressure to give crude product, which was purified over SiO_2 using hexane-EtOAc (5:1) as eluant to furnish pure **16** (2 g, 78%); colorless solid; m.p. $86\text{--}88^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{25} -53.6$ (c 1.5, CHCl_3); IR (KBr): 2927, 2859, 1754, 1509, 1457, 1371, 1247, 1222, 1179, 1092, 1040, 1000, 828, 749, 699 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.47–7.01 (m, 37 H, Ar-H), 6.90 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.82–6.75 (m, 4 H, Ar-H), 5.50 (s, 1 H, PhCH), 5.32 (s, 1 H, PhCH), 5.30 (d, $J=1.6$ Hz, 1 H, H-1_A), 5.10 (br s, 1 H, H-1_D), 5.02 (2 d, $J=7.7$ Hz, 2 H, H-1_B and H-1_C), 4.97 (d, $J=11.7$ Hz, 1 H, PhCH₂), 4.93–4.90 (m, 2 H, H-2_E and PhCH₂), 4.88–4.68 (m, 6 H, PhCH₂), 4.65–4.58 (m, 2 H, H-3_E and PhCH₂), 4.55–4.44 (m, 3 H, PhCH₂), 4.41 (d, $J=7.2$ Hz, 1 H, H-1_E), 4.35–4.23 (m, 4 H, H-3_A, H-3_D, H-4_E and H-6_{aC}), 3.97 (t, $J=8.0$ Hz, 1 H, H-3_C), 3.96–3.88 (m, 2 H, H-2_A and H-5_{aE}), 3.85–3.77 (m, 3 H, H-2_D, H-4_A and H-5_{bE}), 3.75 (s, 6 H, 2 OCH₃), 3.74–3.70 (m, 2 H, H-5_A and H-6_{bC}), 3.68–3.58 (m, 3 H, H-3_B, H-4_D and H-6_{aB}), 3.57–3.50 (m, 1 H, H-4_B), 3.49–3.35 (m, 4 H, H-2_B, H-4_C, H-5_D and H-6_{bB}), 3.32–2.22 (m, 2 H, H-2_C and H-5_C), 2.82–2.72 (m, 1 H, H-5_B), 2.03, 2.01 (2 s, 9 H, 3 COCH₃), 1.25 (d, $J=9.0$ Hz, 3 H, CCH₃), 0.85 (d, $J=9.0$ Hz, 3 H, CCH₃); ^{13}C NMR (75 MHz, CDCl_3): δ 169.9, 169.8 (2 C) (3 COCH₃), 159.5–113.7 (Ar-C), 103.4 (C-1_C), 102.5 (C-1_B), 101.9 (C-1_E), 101.5 (PhCH), 101.3 (PhCH), 99.2 (C-1_D), 97.2 (C-1_A), 83.2 (C-2_B), 82.5 (C-5_C), 81.5 (C-5_B), 80.5 (C-2_C), 79.4 (2 C, C-4_A and C-4_B), 78.5 (C-2_A), 78.0 (C-4_D), 76.9 (C-3_A), 75.0 (2 C, PhCH₂), 74.4 (PhCH₂), 74.2 (PhCH₂), 73.6 (PhCH₂), 72.2 (PhCH₂), 71.2 (C-4_E), 71.0 (C-2_E), 70.6 (C-3_E), 69.5 (C-2_D), 69.3 (C-3_B), 69.0 (2 C, C-5_E and C-6_C), 68.8 (C-5_D), 68.6 (C-3_D), 67.8 (C-3_C), 66.2 (C-5_A), 66.0 (C-4_C), 61.3 (C-6_B), 55.5, 55.0 (2 OCH₃), 20.6 (3 C, 3 COCH₃), 17.9, 17.3 (2 CCH₃); ESI-MS: $m/z=1762.8$ $[\text{M}+\text{NH}_4]^+$; Anal. Calcd. for $\text{C}_{99}\text{H}_{108}\text{O}_{28}$ (1744.70): C, 68.11; H, 6.24; found: C, 67.92; H, 6.46.

4-Methoxyphenyl (2,3,4-tri-O-acetyl- β -D-xylopyranosyl)-(1 \rightarrow 2)-(4-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4-di-O-benzyl- α -L-rhamnopyranoside (17) To a solution of compound **16** (1.8 g, 1 mmol) in CH_2Cl_2 and water (30 mL, 1:1), was added DDQ (270 mg, 1.2 mmol) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with CH_2Cl_2 (30 mL)

and the organic layer was washed in succession with satd. aq NaHCO_3 and water, dried (Na_2SO_4) and concentrated under reduced pressure to give the crude product, which was purified over SiO_2 using hexane-EtOAc (3:1) as eluant to furnish pure **17** (1.3 g, 80%); colorless solid; m.p. $104\text{--}106^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{25} -36.9$ (c 1.5, CHCl_3); IR (KBr): 2925, 1749, 1605, 1375, 1224, 1086, 761 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.47–7.02 (m, 35 H, Ar-H), 6.88 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.78 (d, $J=9.0$ Hz, 2 H, Ar-H), 5.50 (s, 1 H, PhCH), 5.30 (s, 1 H, PhCH), 5.29 (br s, 1 H, H-1_A), 5.05 (br s, 1 H, H-1_D), 5.02–4.88 (m, H-1_B, H-1_C and PhCH₂), 4.85–4.72 (m, 3 H, H-2_E and PhCH₂), 4.70–4.66 (m, 2 H, PhCH₂), 4.64–4.50 (m, 4 H, H-3_E and PhCH₂), 4.35–4.27 (m, 3 H, H-3_A, H-3_D and H-4_E), 4.25–4.17 (m, 1 H, H-6_{aC}), 4.10 (d, $J=7.2$ Hz, 1 H, H-1_E), 4.00 (t, $J=7.9$ Hz, 1 H, H-3_C), 3.94–3.92 (m, 1 H, H-2_A), 3.87–3.76 (m, 5 H, H-3_B, H-4_A, H-4_C, H-5_D and H-5_{aE}), 3.74 (s, 3 H, OCH₃), 3.70–3.60 (m, 4 H, H-2_D, H-5_B, H-5_{bE} and H-6_{bC}), 3.58–3.50 (m, 2 H, H-4_B and H-6_{aB}), 3.48–3.35 (m, 3 H, H-2_B, H-2_C and H-5_A), 3.32–3.23 (m, 1 H, H-5_C), 3.07 (t, $J=7.9$ Hz, 1 H, H-4_D), 2.68–2.58 (m, 1 H, H-6_{bB}), 2.06, 2.05, 2.03 (3 s, 9 H, 3 COCH₃), 1.24 (d, $J=6.0$ Hz, 3 H, CCH₃), 0.80 (d, $J=6.0$ Hz, 3 H, CCH₃); ^{13}C NMR (75 MHz, CDCl_3): δ 169.6, 169.5, 169.2 (3 COCH₃), 154.8–114.4 (Ar-C), 103.2 (C-1_C), 102.4 (C-1_B), 102.1 (C-1_E), 101.5 (PhCH), 101.2 (PhCH), 98.7 (C-1_D), 97.1 (C-1_A), 83.0 (C-2_B), 82.8 (C-5_C), 81.9 (C-4_D), 81.3 (C-2_C), 80.3 (C-5_B), 79.3 (C-4_A), 79.2 (C-4_B), 78.4 (C-2_A), 78.1 (C-2_D), 77.2 (C-3_A), 74.9 (PhCH₂), 74.4 (2 C, PhCH₂), 74.3 (PhCH₂), 73.5 (PhCH₂), 71.3 (C-4_E), 71.2 (C-3_C), 70.9 (C-2_E), 70.7 (C-3_E), 69.3 (C-3_B), 69.2 (C-5_D), 68.9 (2 C, C-5_E and C-6_C), 68.4 (C-3_D), 66.9 (C-5_A), 66.0 (C-4_C), 61.4 (C-6_B), 55.3 (OCH₃), 20.5 (3 C, 3 COCH₃), 17.8, 17.2 (2 CCH₃); ESI-MS: $m/z=1642.7$ $[\text{M}+\text{NH}_4]^+$; Anal. Calcd. for $\text{C}_{91}\text{H}_{100}\text{O}_{27}$ (1624.64): C, 67.23; H, 6.20; found: C, 67.02; H, 6.44.

4-Methoxyphenyl [4-O-benzyl-3-O-methyl-2-O-(4-methoxybenzyl)- α -L-rhamnopyranosyl]-(1 \rightarrow 3)-[(2,3,4-tri-O-acetyl- β -D-xylopyranosyl)-(1 \rightarrow 2)]-(4-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4-di-O-benzyl- α -L-rhamnopyranoside (18) To a solution of compound **17** (1.2 g, 0.74 mmol) and compound **6** (390 mg, 0.9 mmol) in dry CH_2Cl_2 (20 mL) was added MS 4 Å (1 g) and the reaction mixture was stirred at room temperature for 30 min under argon. The reaction mixture was cooled to -30°C and *N*-iodosuccinimide (225 mg, 1 mmol) and TMSOTf (10 μL , 0.05 mmol) were added to it. The mixture was stirred at the same temperature for 30 min and quenched with Et_3N (0.1 mL). The reaction mixture was filtered and washed with CH_2Cl_2 (50 mL). The organic layer was washed successively with 10% aq $\text{Na}_2\text{S}_2\text{O}_3$ and water, dried

(Na₂SO₄) and concentrated under reduced pressure to give crude product, which was purified over SiO₂ using hexane-EtOAc (5:1) as eluant to furnish pure **18** (1.1 g, 74%); colorless solid; m.p. 78–80°C; [α]_D²⁵ –35.6 (*c* 1.5, CHCl₃); IR (KBr): 2926, 2363, 1752, 1707, 1652, 1510, 1458, 1374, 1223, 1090, 698 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.15 (m, 40 H, Ar-H), 7.06–7.02 (m, 2 H, Ar-H), 6.90 (d, *J*=9.0 Hz, 2 H, Ar-H), 6.78–6.70 (m, 4 H, Ar-H), 5.51 (s, 1 H, PhCH), 5.30 (d, *J*=1.7 Hz, 1 H, H-1_A), 5.28 (s, 1 H, PhCH), 5.08 (br s, 1 H, H-1_D), 5.05 (br s, 1 H, H-1_F), 5.04–5.0 (m, 2 H, H-2_E and PhCH₂), 4.97 (d, *J*=7.8 Hz, 1 H, H-1_B), 4.94–4.91 (m, 1 H, H-3_E), 4.90 (d, *J*=8.1 Hz, 1 H, H-1_C), 4.89–4.76 (m, 6 H, PhCH₂), 4.70 (d, *J*=7.2 Hz, 1 H, H-1_E), 4.67–4.61 (m, 3 H, H-4_E and PhCH₂), 4.60–4.43 (m, 4 H, PhCH₂), 4.38–4.20 (m, 6 H, H-3_A, H-3_B, H-3_D, H-3_F, H-6_{aC}, PhCH₂), 4.06–3.92 (m, 3 H, H-2_A, H-3_C, H-4_F), 3.88–3.72 (m, 3 H, H-2_D, H-5_A and H-6_{bC}), 3.74 (s, 3 H, OCH₃), 3.69 (s, 3 H, OCH₃), 3.67–3.57 (m, 6 H, H-2_F, H-4_B, H-5_D, H-5_{aE}, H-5_F and H-6_{aB}), 3.55–3.38 (m, 5 H, H-2_B, H-2_C, H-4_A, H-4_D and H-5_{bE}), 3.35 (s, 3 H, OCH₃), 3.34–3.23 (m, 2 H, H-4_C and H-5_B), 3.22–3.14 (m, 1 H, H-5_C), 2.96–2.88 (m, 1 H, H-6_{bB}), 2.04, 2.01, 2.0 (3 s, 9 H, 3 COCH₃), 1.30 (d, *J*=6.1 Hz, 3 H, CCH₃), 1.25 (d, *J*=6.1 Hz, 3 H, CCH₃), 0.81 (d, *J*=6.0 Hz, 3 H, CCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 169.4, 169.1, 168.6 (3 COCH₃), 159.6–113.4 (Ar-C), 103.3 (C-1_C), 102.0 (C-1_B), 101.2 (2 C, 2 PhCH), 100.7 (C-1_E), 99.4 (C-1_F), 98.7 (C-1_D), 97.1 (C-1_A), 83.2 (C-2_F), 81.8 (C-5_F), 81.6 (C-2_C), 81.3 (2 C, C-4_A and C-4_D), 80.9 (C-2_B), 80.2 (C-5_C), 79.3 (C-4_B), 78.9 (C-2_D), 78.4 (C-2_A), 77.4 (C-5_B), 77.2 (C-3_B), 76.7 (2 C, C-3_A and C-3_C), 76.1 (C-5_D), 74.8 (3 C, PhCH₂), 74.3 (C-3_F), 74.2 (PhCH₂), 73.8 (PhCH₂), 73.5 (PhCH₂), 71.9 (PhCH₂), 70.9 (C-3_D), 70.7 (C-4_E), 68.6 (2 C, C-5_E and C-6_C), 68.5 (2 C, C-2_E and C-5_A), 68.4 (C-3_E), 66.1 (C-4_F), 65.8 (C-4_C), 61.2 (C-6_B), 57.3 (OCH₃), 55.3, 54.8 (2 OCH₃); ESI-MS: *m/z*=2012.8 [M+NH₄]⁺; Anal. Calcd. for C₁₁₃H₁₂₆O₃₂ (1994.82): C, 67.99; H, 6.36; found: C, 67.78; H, 6.60.

4-Methoxyphenyl (4-O-benzyl-3-O-methyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4-tri-O-acetyl- β -D-xylopyranosyl)-(1 \rightarrow 2)]-(4-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4-di-O-benzyl- α -L-rhamnopyranoside (19**)** To a solution of compound **18** (1 g, 0.5 mmol) in CH₂Cl₂ and water (20 mL, 1:1), was added DDQ (140 mg, 0.6 mmol) and the reaction mixture was stirred at room temperature for 2 h and diluted with CH₂Cl₂ (30 mL). The organic layer was washed successively with satd. aq NaHCO₃ and water, dried (Na₂SO₄) and concentrated under reduced pressure to give the crude product, which was purified over SiO₂ using hexane-EtOAc (5:1) as eluant to furnish pure **19** (750 mg,

80%); colorless solid; m.p. 98–100°C; [α]_D²⁵ –51.6 (*c* 1.5, CHCl₃); IR (KBr): 3021, 2363, 1757, 1593, 1372, 1216, 1087, 760, 670 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.49–7.06 (m, 40 H, Ar-H), 6.90 (d, *J*=9.0 Hz, 2 H, Ar-H), 6.77 (d, *J*=9.0 Hz, 2 H, Ar-H), 5.50 (s, 1 H, PhCH), 5.29 (br s, 1 H, H-1_A), 5.24 (s, 1 H, PhCH), 5.08 (br s, 2 H, H-1_D and H-1_F), 5.04–4.99 (m, 3 H, H-1_B, H-1_C and PhCH₂), 4.98–4.94 (m, 1 H, H-2_E), 4.90–4.80 (m, 5 H, PhCH₂), 4.77–4.60 (m, 4 H, H-1_E and PhCH₂), 4.58–4.45 (m, 4 H, H-3_E, H-4_E and PhCH₂), 4.38–4.30 (m, 4 H, H-3_A, H-3_D, H-3_F and PhCH₂), 4.28–4.19 (m, 1 H, H-6_{aC}), 4.05–3.90 (m, 5 H, H-2_A, H-2_F, H-3_B, H-3_C and H-4_B), 3.88–3.76 (m, 4 H, H-2_D, H-4_F, H-5_A, H-6_{bC}), 3.74 (s, 3 H, OCH₃), 3.72–3.52 (m, 4 H, H-5_D, H-5_F, H-5_{aE} and H-6_{aB}), 3.50–3.40 (m, 4 H, H-2_B, H-2_C, H-4_A and H-5_{bE}), 3.39 (s, 3 H, OCH₃), 3.38–3.26 (m, 3 H, H-4_C, H-4_D and H-5_B), 3.25–3.16 (m, 1 H, H-5_C), 2.97–2.86 (m, 1 H, H-6_{bB}), 2.01, 1.96 (2 s, 9 H, 3 COCH₃), 1.30 (d, *J*=6.0 Hz, 3 H, CCH₃), 1.25 (d, *J*=6.0 Hz, 3 H, CCH₃), 0.85 (d, *J*=6.0 Hz, 1 H, CCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 169.2, 169.0, 168.6 (3 COCH₃), 154.8–117.5 (Ar-C), 103.2 (C-1_C), 102.0 (C-1_B), 101.3 (PhCH), 101.2 (PhCH), 100.7 (2 C, C-1_E and C-1_F), 98.7 (C-1_D), 97.1 (C-1_A), 83.5 (C-5_C), 83.2 (C-2_F), 81.9 (C-2_C), 81.5 (C-4_A), 81.4 (C-4_D), 81.0 (C-2_B), 79.6 (C-5_F), 79.3 (C-4_B), 79.0 (C-2_D), 78.4 (C-2_A), 77.5 (2 C, C-3_B and C-5_B), 76.9 (C-3_C), 76.2 (C-3_A), 74.8 (2 C, PhCH₂), 74.7 (PhCH₂), 74.3 (PhCH₂), 73.8 (PhCH₂), 73.5 (PhCH₂), 70.7 (C-5_D), 70.6 (C-3_F), 68.7 (2 C, C-5_E and C-6_C), 68.5 (2 C, C-3_D and C-4_E), 68.0 (C-2_E), 67.7 (C-3_E), 67.6 (C-5_A), 66.0 (C-4_F), 65.8 (C-4_C), 61.2 (C-6_B), 57.1 (OCH₃), 55.3 (OCH₃), 20.7, 20.5 (2 C) (3 COCH₃), 18.2, 17.8, 17.2 (3 CCH₃); ESI-MS: *m/z*=1897.8 [M+Na]⁺; Anal. Calcd. for C₁₀₅H₁₁₈O₃₁ (1874.76): C, 67.22; H, 6.34; found: C, 67.0; H, 6.58.

4-Methoxyphenyl (2,3,4-tri-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 2)-(4-O-benzyl-3-O-methyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[(2,3,4-tri-O-acetyl- β -D-xylopyranosyl)-(1 \rightarrow 2)]-(4-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-(2-O-benzyl-4,6-O-benzylidene- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4-di-O-benzyl- α -L-rhamnopyranoside (20**)** To a solution of compound **19** (700 mg, 0.37 mmol) and compound **4** (190 mg, 0.57 mmol) in dry CH₂Cl₂ (20 mL) was added MS 4 Å (3 g) and the reaction mixture was stirred at room temperature for 30 min under argon. The reaction mixture was cooled to –30°C and *N*-iodosuccinimide (150 mg, 0.66 mmol) and TMSOTf (5 μ L, 0.03 mmol) were added to it. The reaction mixture was stirred at the same temperature for 30 min and quenched with Et₃N (50 μ L). The reaction mixture was filtered and washed with CH₂Cl₂ (30 mL). The organic layer was successively washed with 10% aq Na₂S₂O₃ and water,

dried (Na_2SO_4) and concentrated under reduced pressure to give crude product, which was purified over SiO_2 using hexane-EtOAc (5:1) as eluant to furnish pure **20** (675 mg, 85%); colorless solid; m.p. 95–97°C; $[\alpha]_{\text{D}}^{25}$ –45 (*c* 1.5, CHCl_3); IR (KBr): 3021, 2925, 2365, 1753, 1662, 1600, 1369, 1219, 1085, 761 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.48–7.02 (m, 40 H, Ar-H), 6.89 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.78 (d, $J=9.0$ Hz, 2 H, Ar-H), 5.30 (s, 1 h, PhCH), 5.40–5.20 (m, 4 H, H-1_A, H-2_G, H-3_G and PhCH), 5.14–4.78 (m, 10 H, H-1_B, H-1_C, H-1_D, H-1_F, H-1_G, H-2_E, H-4_G and PhCH₂), 4.75–4.60 (m, 7 H, H-1_E, H-3_E, H-4_E and PhCH₂), 4.58–4.43 (m, 4 H, PhCH₂), 4.40–4.20 (m, 5 H, H-3_A, H-3_D, H-3_F, H-6_{aC} and PhCH₂), 4.13–4.07 (m, 1 H, H-3_B), 4.05–3.90 (m, 5 H, H-2_A, H-2_D, H-2_F, H-3_C and H-4_B), 3.88–3.70 (m, 4 H, H-4_F, H-5_A, H-5_G and H-6_{bC}), 3.75 (s, 3 H, (OCH₃)), 3.68–3.50 (m, 6 H, H-4_A, H-4_D, H-5_D, H-5_F, H-5_{aE} and H-6_{aB}), 3.46 (s, 3 H, OCH₃), 3.44–3.10 (m, 6 H, H-2_B, H-2_C, H-4_C, H-5_B, H-5_C and H-5_{bE}), 2.98–2.88 (m, 1 H, H-6_{bB}), 2.05, 2.04, 2.02, 2.01, 2.00, 1.98 (6 s, 18 H, 6 COCH₃), 1.31–1.20 (m, 9 H, 3 CCH₃), 0.87 (d, $J=6.0$ Hz, CCH₃); ^{13}C NMR (75 MHz, CDCl_3): δ 169.9–168.4 (6 COCH₃), 154.8–114.5 (Ar-C), 102.2 (C-1_C), 101.1 (C-1_B), 100.2 (2 C, PhCH), 99.6 (C-1_F), 99.4 (C-1_E), 97.7 (2 C, C-1_D and C-1_G), 96.1 (C-1_A), 83.2 (C-5_C), 82.2 (C-2_F), 81.4 (3 C, C-2_C, C-4_A and C-4_D), 81.0 (C-5_G), 80.0 (C-2_B), 79.4 (C-5_F), 79.1 (C-4_B), 78.5 (C-2_D), 77.7 (C-2_A), 77.6 (C-3_B), 77.2 (C-5_B), 76.8 (C-3_C), 76.4 (C-3_A), 75.2 (C-3_F), 75.1 (PhCH₂), 75.9 (PhCH₂), 74.7 (PhCH₂), 74.4 (PhCH₂), 74.0 (PhCH₂), 73.6 (PhCH₂), 70.9 (3 C, C-3_D, C-4_E and C-5_D), 70.8 (C-4_G), 69.7 (C-2_G), 68.9 (C-3_G), 68.8 (2 C, C-5_E and C-6_C), 68.5 (2 C, C-2_E and C-3_E), 67.8 (C-5_A), 66.8 (C-4_F), 66.2 (C-4_C), 61.5 (C-6_B), 57.9 (OCH₃), 55.4 (OCH₃), 20.8–20.6 (6 COCH₃), 18.3, 17.9, 17.2, 17.1 (4 CCH₃); ESI-MS: $m/z=2165.0$ $[\text{M}+\text{NH}_4]^+$; Anal. Calcd. for $\text{C}_{117}\text{H}_{134}\text{O}_{38}$ (2146.85): C, 65.41; H, 6.29; found: C, 65.22; H, 6.55.

4-Methoxyphenyl (α -L-rhamnopyranosyl)-(1→2)-(3-O-methyl- α -L-rhamnopyranosyl)-(1→3)-[(β -D-xylopyranosyl)-(1→2)]-(α -L-rhamnopyranosyl)-(1→3)-(β -D-glucopyranosyl)-(1→3)-(β -D-glucopyranosyl)-(1→3)- α -L-rhamnopyranoside (I) A solution of compound **20** (650 mg, 0.3 mmol) in 0.1 M CH_3ONa in CH_3OH (10 mL) was allowed to stir at room temperature for 2 h. The reaction mixture was neutralized with Dowex 50 W X-8 (H^+) resin, filtered and concentrated. To a solution of the crude product in CH_3OH (10 mL) was added 20% $\text{Pd}(\text{OH})_2/\text{C}$ (150 mg) and the reaction mixture was allowed to stir at room temperature under a positive pressure of hydrogen for 24 h. The reaction mixture was filtered through a Celite® bed and evaporated to dryness to give heptasaccharide **1**, which was purified through a Sephadex LH-20 column using CH_3OH -water (8:1) as eluant (270 mg, 76%); white powder; $[\alpha]_{\text{D}}^{25}$ –52.3

(*c* 1.0, H_2O); IR (KBr): 2926, 2373, 1759, 1658, 1550, 1467, 1429, 1370, 1045, 679 cm^{-1} ; ^1H NMR (300 MHz, D_2O): δ 7.0 (d, $J=9.0$ Hz, 2 H, Ar-H), 6.88 (d, $J=9.0$ Hz, 2 H, Ar-H), 5.39 (br s, 1 H, H-1_G), 5.33 (br s, 1 H, H-1_A), 5.26 (br s, 1 H, H-1_D), 4.92 (br s, 1 H, H-1_F), 4.70 (d, $J=7.5$ Hz, 1 H, H-1_B), 4.63 (d, $J=7.5$ Hz, 1 H, H-1_C), 4.54 (d, $J=7.2$ Hz, 1 H, H-1_E), 4.30 (br s, 1 H, H-2_A), 4.23 (br s, 1 H, H-2_D), 4.07–4.03 (m, 2 H, H-2_G and H-3_A), 4.0–3.82 (m, 6 H, H-2_F, H-4_B, H-4_G, H-5_{aE} and H-6_{aB}), 3.80–3.78 (m, 1 H, H-3_F), 3.76 (s, 3 H, OCH₃), 3.70–3.61 (m, 5 H, H-3_E, H-3_G, H-4_F and H-6_{aB}), 3.60–3.51 (m, 7 H, H-2_B, H-3_B, H-3_C, H-3_D, H-4_A, H-4_D, H-5_G), 3.50 (s, 3 H, OCH₃), 3.45–3.30 (m, 10 H, H-2_C, H-2_E, H-4_C, H-4_E, H-5_A, H-5_B, H-5_C, H-5_D, H-5_{bE}, H-5_F), 1.36–1.27 (m, 9 H, 3 CCH₃), 0.91 (d, $J=6.0$ Hz, 3 H, CCH₃); ^{13}C NMR (75 MHz, D_2O): δ 155.0–114.2 (Ar-C), 105.0 (C-1_E), 103.9 (C-1_B), 103.5 (C-1_C), 101.7 (C-1_F), 100.7 (C-1_D), 100.0 (C-1_G), 99.0 (C-1_A), 85.9 (C-3_G), 82.1 (C-3_D), 81.2 (C-2_G), 80.4 (C-5_G), 78.8 (C-3_A), 76.5 (C-4_C), 76.0 (2 C, C-2_C, C-4_G), 75.9 (C-4_E), 74.7 (C-5_F), 73.6 (C-4_A), 73.3 (C-2_D), 73.1 (C-3_C), 72.4 (2 C, C-2_B, C-4_B), 71.8 (C-5_B), 71.2 (C-2_A), 70.8 (C-2_E), 70.7 (C-5_A), 70.0 (C-4_F), 69.7 (C-3_B), 69.2 (C-3_E), 68.8 (2 C, C-5_C, C-5_D), 68.7 (C-3_F), 68.5 (C-4_D), 68.1 (C-2_F), 65.4 (C-5_E), 61.1 (C-6_B), 60.6 (C-6_C), 56.7 (OCH₃), 54.6 (OCH₃), 16.8, 16.6, 16.4, 16.3 (4 CCH₃); ESI-MS: $m/z=1201.5$ $[\text{M}+\text{Na}]^+$; Anal. Calcd. for $\text{C}_{49}\text{H}_{78}\text{O}_{32}$ (1178.45): C, 49.91; H, 6.67; found: C, 49.67; H, 6.96.

Acknowledgements Instrumentation facilities from SAIF, CDRI is gratefully acknowledged. R.P. thanks CSIR, New Delhi for providing a Junior Research fellowship. This work was supported by Ramanna Fellowship (AKM), Department of Science and Technology, New Delhi (SR/S1/RFPC-06/2006).

References

- Busillo, C., Lessnau, K.D., Soumakis, S., Davidson, M., Mullen, M.P., Talavera, W.: Multidrug resistant *Mycobacterium tuberculosis* in patients with human immunodeficiency virus infection. *Chest* **102**, 797–801 (1992)
- Weinberger, M., Berg, S.L., Feuerstein, I.M., Pizzo, P.A., Witebsky, F.G.: Disseminated infection with *Mycobacterium gordonae*: report of a case and critical review of the literature. *Clin. Infect. Dis.* **14**, 1229–1239 (1992)
- Wayne, L., Sramek, H.: Agents of newly recognized or infrequently encountered mycobacterial diseases. *Clin. Microbiol. Rev.* **5**, 1–25 (1992)
- Wallace Jr, R.J., Brown, B.A., Griffith, D.E.: Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. *Annu. Rev. Microbiol.* **52**, 453–490 (1998)
- Lai, K.K., Brown, B.A., Westerling, J.A., Fontecchio, S.A., Zhang, Y., Wallace, R.J. Jr.: *Clin. Infect. Dis.* **27**, 169–175 (1998)
- Lessnau, K.D., Milanese, S., Talavera, W.: *Mycobacterium gordonae*: a treatable disease in HIV-positive patients. *Chest* **104**, 1779–1785 (1993)
- Chapman, S.J.: The atypical mycobacteria and human mycobacteriosis, pp. 86–90. Plenum, New York and London (1977)

8. Barber, T.W., Craven, D.E., Farber, H.W.: *Mycobacterium gordonae*: a possible opportunistic respiratory tract pathogen in patients with advanced human immunodeficiency virus, type 1 infection. *Chest* **100**, 716–720 (1991)
9. Stine, T.M., Harris, A.A., Levin, S., Rivera, N., Kaplan, R.L.: A pseudoepidemic due to atypical mycobacteria in a hospital water supply. *JAMA* **258**, 809–811 (1987)
10. Besra, G.S., McNeil, M.R., Khoo, K.-H., Dell, A., Morris, H.R., Brennan, P.J.: Trehalose-containing lipooligosaccharides of *Mycobacterium gordonae*: presence of a mono-*O*-methyltetra-*O*-acyltrehalose “core” and branching in the oligosaccharide backbone. *Biochemistry* **32**, 12705–12714 (1993)
11. Roy, R.: New trends in carbohydrate-based vaccines. *Drug Discov. Today: technologies* **1**, 327–336 (2004) and references cited therein
12. Verez-Bencomo, V., Fernández-Santana, V., Hardy, E., Toledo, M.E., Rodríguez, M.C., Heynngnezz, L., Rodríguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdés, Y., Cosme, K., Deler, M.L., Montane, M., García, E., Ramos, A., Aguilar, A., Medina, E., Torano, G., Sosa, I., Hernandez, I., Martínez, R., Muzachio, A., Carmentales, A., Costa, L., Cardoso, F., Campa, C., Diaz, M., Roy, R.A.: Synthetic conjugate polysaccharide vaccine against *Haemophilus influenzae* Type b. *Science* **305**, 522–525 (2004)
13. Pozsgay, V.: Synthetic *Shigella* vaccines: a carbohydrate-protein conjugate with totally synthetic hexadecasaccharide haptens. *Angew. Chem. Int. Ed. Engl.* **37**, 138–142 (1998)
14. Taylor, R.K., Kirm, T.J., Bose, N., Stonehouse, E., Tripathi, S.A., Kovác, P., Wade, W.F.: Progress towards development of a cholera subunit vaccine. *Chem. Biodivers.* **1**, 2036–2057 (2004)
15. Meeks, M.D., Saksena, R., Ma, X., Wade, T.K., Taylor, R.K., Kovác, P., Wade, W.F.: Synthetic fragments of *Vibrio cholerae* O:1 Inaba O-SP Bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. *Infect. Immun.* **72**, 4090–4101 (2004)
16. Snippe, H., van Dam, J.E.G., van Houte, A.J., Willers, J.M.N., Kamerling, J.P., Vliegthart, J.F.G.: Preparation of a semisynthetic vaccine to *Streptococcus pneumoniae* type 3. *Infect. Immun.* **42**, 842–844 (1983)
17. Michalik, D., Vliegthart, J.F.G., Kamerling, J.P.: Chemoenzymic synthesis of oligosaccharide fragments of the capsular polysaccharide of *Streptococcus pneumoniae* type 14. *J. Chem. Soc., Perkin Trans.* **1**, 1973–1981 (2002)
18. Jansen, W.T.M., Hogenboom, S., Thijssen, M.J.L., Kamerling, J.P., Vliegthart, J.F.G., Verhoef, J., Snippe, H., Verheul, A.F.: Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. *Infect. Immun.* **69**, 787–793 (2001)
19. Tamborini, M., Werz, D.B., Frey, J., Pluschke, G., Seeberger, P.H.: Anti-carbohydrate antibodies for the detection of anthrax spores. *Angew. Chem. Int. Ed. Engl.* **45**, 6581–6582 (2006)
20. Schofield, L., Hewitt, M.C., Evans, K., Siomos, M.-A., Seeberger, P.H.: Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. *Nature* **418**, 785–789 (2002)
21. Descoteaux, A., Turco, S.J.: Functional aspects of the *Leishmania donovani* lipophosphoglycan during macrophage function. *Microbes. Infect.* **4**, 975–981 (2002)
22. Gurjar, M.K., Adhikari, S.: Synthesis of the unique terminal branched tetrasaccharide of *Mycobacterium gordonae* strain 990. *Tetrahedron* **53**, 8629–8634 (1997)
23. Mukherjee, C.M., Misra, A.K.: Total synthesis of an antigenic heptasaccharide motif found in the cell-wall lipooligosaccharide of *Mycobacterium gordonae* strain 989. *Glycoconjugate J.* published Online-First (2008); doi:10.1007/s10719-008-9107-y
24. Zuurmond, H.M., van der Klein, P.A.M., van der Marel, G.A., van Boom, J.H.: A stereospecific approach towards the synthesis of 2-deoxy a- and b-glycosides based on a 1,2-ethyl (phenyl) thio group migration. *Tetrahedron* **49**, 6501–6514 (1993)
25. Veeneman, G.H., van Leeuwen, S.H., van Boom, J.H.: Iodonium ion promoted reactions at the anomeric centre. II An efficient thioglycoside mediated approach toward the formation of 1,2-*trans* linked glycosides and glycosidic esters. *Tetrahedron Lett.* **31**, 1331–1334 (1990)
26. Konradsson, P., Udodong, U.E., Fraser-Reid, B.: Iodonium promoted reactions of disarmed thioglycosides. *Tetrahedron Lett.* **31**, 4313–4316 (1990)
27. Madhusudan, S.K., Agnihotri, G., Negi, D.S., Misra, A.K.: Direct one-pot conversion of acylated carbohydrates into their alkylated derivatives under heterogeneous reaction conditions using solid NaOH and a phase transfer catalyst. *Carbohydr. Res.* **340**, 1373–1377 (2005)
28. Okiawa, Y., Yoshioko, T., Yonemitsu, O.: Specific removal of *O*-methoxybenzyl protection by DDQ oxidation. *Tetrahedron Lett.* **23**, 885–888 (1982)
29. Bock, K., Pederson, C.: A study of ¹³C coupling constants in hexopyranoses. *J. Chem. Soc. Perkin. Trans.* **2**, 293–297 (1974)
30. Pearlmann, W.M.: Noble metal hydroxides on carbon nonpyrophoric dry catalysts. *Tetrahedron Lett.* **8**, 1663–1664 (1967)